Evofem Biosciences, Inc. filed its 10-K on Apr 27, 2023 for the period ending Dec 31, 2022. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.012 USD | -7.69% |
|
+3.45% | -81.25% |
May. 16 | Transcript : Evofem Biosciences, Inc. - Special Call | |
May. 15 | Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
1st Jan change | Capi. | |
---|---|---|
-81.25% | 1.03M | |
+51.27% | 791B | |
+41.41% | 630B | |
+17.68% | 328B | |
+9.40% | 298B | |
+17.36% | 246B | |
+0.49% | 225B | |
+9.92% | 218B | |
+3.20% | 160B | |
-5.68% | 156B |
- Stock Market
- Equities
- EVFM Stock
- News Evofem Biosciences, Inc.
- Evofem Biosciences, Inc. Auditor Raises 'Going Concern' Doubt